Annual Cash & Cash Equivalents
$3.38 M
-$14.97 M-81.59%
December 31, 2023
Summary
- As of February 7, 2025, CYCC annual cash & cash equivalents is $3.38 million, with the most recent change of -$14.97 million (-81.59%) on December 31, 2023.
- During the last 3 years, CYCC annual cash & cash equivalents has fallen by -$30.03 million (-89.89%).
- CYCC annual cash & cash equivalents is now -92.36% below its all-time high of $44.24 million, reached on December 31, 2006.
Performance
CYCC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.98 M
-$3.02 M-50.30%
September 30, 2024
Summary
- As of February 7, 2025, CYCC quarterly cash and cash equivalents is $2.98 million, with the most recent change of -$3.02 million (-50.30%) on September 30, 2024.
- Over the past year, CYCC quarterly cash and cash equivalents has dropped by -$396.00 thousand (-11.72%).
- CYCC quarterly cash and cash equivalents is now -96.04% below its all-time high of $75.22 million, reached on March 31, 2007.
Performance
CYCC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CYCC Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -81.6% | -11.7% |
| 3 y3 years | -89.9% | -73.9% |
| 5 y5 years | -80.7% | -73.9% |
CYCC Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -90.8% | at low | -91.8% | +6.6% |
| 5 y | 5-year | -90.8% | at low | -93.8% | +6.6% |
| alltime | all time | -92.4% | +50.7% | -96.0% | +33.1% |
Cyclacel Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.98 M(-50.3%) |
| Jun 2024 | - | $6.00 M(+114.4%) |
| Mar 2024 | - | $2.80 M(-17.2%) |
| Dec 2023 | $3.38 M(-81.6%) | $3.38 M(-43.2%) |
| Sep 2023 | - | $5.94 M(-41.5%) |
| Jun 2023 | - | $10.16 M(-11.1%) |
| Mar 2023 | - | $11.44 M(-37.7%) |
| Dec 2022 | $18.34 M(-49.8%) | $18.34 M(-22.6%) |
| Sep 2022 | - | $23.71 M(-18.5%) |
| Jun 2022 | - | $29.08 M(-1.9%) |
| Mar 2022 | - | $29.64 M(-18.9%) |
| Dec 2021 | $36.56 M(+9.4%) | $36.56 M(-9.1%) |
| Sep 2021 | - | $40.22 M(-7.8%) |
| Jun 2021 | - | $43.64 M(-8.7%) |
| Mar 2021 | - | $47.78 M(+43.0%) |
| Dec 2020 | $33.41 M(+181.1%) | $33.41 M(+44.4%) |
| Sep 2020 | - | $23.13 M(-8.7%) |
| Jun 2020 | - | $25.34 M(+184.0%) |
| Mar 2020 | - | $8.92 M(-24.9%) |
| Dec 2019 | $11.88 M(-32.1%) | $11.88 M(-8.3%) |
| Sep 2019 | - | $12.97 M(-14.5%) |
| Jun 2019 | - | $15.16 M(-15.5%) |
| Mar 2019 | - | $17.93 M(+2.5%) |
| Dec 2018 | $17.50 M(-26.8%) | $17.50 M(-7.7%) |
| Sep 2018 | - | $18.97 M(-4.3%) |
| Jun 2018 | - | $19.82 M(-8.8%) |
| Mar 2018 | - | $21.73 M(-9.1%) |
| Dec 2017 | $23.91 M(+44.7%) | $23.91 M(-8.1%) |
| Sep 2017 | - | $26.02 M(+91.5%) |
| Jun 2017 | - | $13.59 M(+6.8%) |
| Mar 2017 | - | $12.73 M(-22.9%) |
| Dec 2016 | $16.52 M(-19.2%) | $16.52 M(-8.4%) |
| Sep 2016 | - | $18.03 M(+13.2%) |
| Jun 2016 | - | $15.93 M(-6.9%) |
| Mar 2016 | - | $17.11 M(-16.3%) |
| Dec 2015 | $20.44 M(-15.5%) | $20.44 M(-10.1%) |
| Sep 2015 | - | $22.73 M(-15.5%) |
| Jun 2015 | - | $26.90 M(-8.4%) |
| Mar 2015 | - | $29.36 M(+21.4%) |
| Dec 2014 | $24.19 M | $24.19 M(-9.4%) |
| Sep 2014 | - | $26.71 M(-20.5%) |
| Jun 2014 | - | $33.58 M(+19.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $28.15 M(-9.6%) |
| Dec 2013 | $31.15 M(+89.8%) | $31.15 M(-9.7%) |
| Sep 2013 | - | $34.49 M(+2.4%) |
| Jun 2013 | - | $33.67 M(+138.1%) |
| Mar 2013 | - | $14.14 M(-13.8%) |
| Dec 2012 | $16.41 M(-32.9%) | $16.41 M(-8.0%) |
| Sep 2012 | - | $17.84 M(-10.7%) |
| Jun 2012 | - | $19.96 M(-15.5%) |
| Mar 2012 | - | $23.64 M(-3.3%) |
| Dec 2011 | $24.45 M(-17.1%) | $24.45 M(-11.7%) |
| Sep 2011 | - | $27.68 M(+34.3%) |
| Jun 2011 | - | $20.61 M(-18.7%) |
| Mar 2011 | - | $25.35 M(-14.1%) |
| Dec 2010 | $29.50 M(+156.6%) | $29.50 M(+59.6%) |
| Sep 2010 | - | $18.48 M(-5.4%) |
| Jun 2010 | - | $19.54 M(-19.2%) |
| Mar 2010 | - | $24.20 M(+110.6%) |
| Dec 2009 | $11.49 M(-52.5%) | $11.49 M(-20.4%) |
| Sep 2009 | - | $14.43 M(-9.0%) |
| Jun 2009 | - | $15.86 M(-22.4%) |
| Mar 2009 | - | $20.44 M(-15.6%) |
| Dec 2008 | $24.22 M(-21.8%) | $24.22 M(-9.4%) |
| Sep 2008 | - | $26.72 M(-15.6%) |
| Jun 2008 | - | $31.68 M(+4.1%) |
| Mar 2008 | - | $30.42 M(-1.8%) |
| Dec 2007 | $30.99 M(-30.0%) | $30.99 M(-0.4%) |
| Sep 2007 | - | $31.11 M(-29.0%) |
| Jun 2007 | - | $43.84 M(-41.7%) |
| Mar 2007 | - | $75.22 M(+70.0%) |
| Dec 2006 | $44.24 M(+1319.2%) | $44.24 M(-11.1%) |
| Sep 2006 | - | $49.79 M(-21.1%) |
| Jun 2006 | - | $63.10 M(+166.2%) |
| Mar 2006 | - | $23.71 M(+660.6%) |
| Dec 2005 | $3.12 M(-77.6%) | $3.12 M(-77.8%) |
| Sep 2005 | - | $14.02 M(+28.0%) |
| Jun 2005 | - | $10.95 M(+151.1%) |
| Mar 2005 | - | $4.36 M(-68.6%) |
| Dec 2004 | $13.90 M(+520.1%) | $13.90 M(+269.8%) |
| Sep 2004 | - | $3.76 M(-57.3%) |
| Jun 2004 | - | $8.80 M(-71.1%) |
| Mar 2004 | - | $30.50 M(+1260.9%) |
| Dec 2003 | $2.24 M | $2.24 M |
FAQ
- What is Cyclacel Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Cyclacel Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of CYCC is $3.38 M
What is the all time high annual cash & cash equivalents for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual cash & cash equivalents is $44.24 M
What is Cyclacel Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, CYCC annual cash & cash equivalents has changed by -$14.97 M (-81.59%)
What is Cyclacel Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CYCC is $2.98 M
What is the all time high quarterly cash and cash equivalents for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly cash and cash equivalents is $75.22 M
What is Cyclacel Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, CYCC quarterly cash and cash equivalents has changed by -$396.00 K (-11.72%)